Mechanism-based prediction of particle size-dependent dissolution and absorption: Cilostazol pharmacokinetics in dogs

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 76, Issue 1, 2010, Pages 83-94

  Willmann, Stefan ^a   Thelen, Kirstin ^a,b   Becker, Corina ^a   Dressman, Jennifer B ^b   Lippert, Jörg ^a  

^a BAYER AG   (Germany)

^b Goethe University Hospital   (Germany)

Author keywords

Absorption; Dissolution; IVIVC; Modeling; Particle size; Simulation

Indexed keywords

CILOSTAZOL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION (PARAMETERS); DIET RESTRICTION; DISSOLUTION; DOG; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG PENETRATION; DRUG SOLUBILITY; FEEDING; GASTROINTESTINAL TRANSIT; IN VITRO STUDY; IN VIVO STUDY; INFORMATION; INTESTINE EPITHELIUM; INTESTINE MUCOSA PERMEABILITY; NONHUMAN; PARTICLE SIZE; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS;

EID: 77955657557     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2010.06.003     Document Type: Article

References (73)

1. Galia E., Nicolaides E., Horter D., Lobenberg R., Reppas C., Dressman J.B. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm. Res. 1998, 15:698-705.
2. Jantratid E., De M., Ronda V.E., Mattavelli V., Vertzoni M., Dressman J.B. Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form. Eur. J. Pharm. Sci. 2009, 37:434-441.
3. Kostewicz E.S., Brauns U., Becker R., Dressman J.B. Forecasting the oral absorption behavior of poorly soluble weak bases using solubility and dissolution studies in biorelevant media. Pharm. Res. 2002, 19:345-349.
4. Nicolaides E., Galia E., Efthymiopoulos C., Dressman J.B., Reppas C. Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data. Pharm. Res. 1999, 16:1876-1882.
5. International Conference on Harmonisation Steering Committee, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use - Draft Consensus Guideline: Pharmaceutical Development Q8, 2004.
6. The European Agency for the Evaluation of Medicinal Products (EMEA), Human Medicines Evaluation Unit, Committee for Proprietary Medicinal Products (CPMP), Note for Guidance on Development Pharmaceutics, 1998.
7. The European Agency for the Evaluation of Medicinal Products (EMEA), Human Medicines Evaluation Unit, Committee for Proprietary Medicinal Products (CPMP), Note for Guidance on Modified Release Oral and Transdermal Dosage Forms: Section II (Pharmacokinetic and Clinical Evaluation), 1999.
8. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations (Guidance for Industry), US Government Printing Office, 1997.
9. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Nonsterile Semisolid Dosage Forms; Scale-Up and Post-Approval Changes: Chemistry, Manufacturing, and Controls; In-Vitro Release Testing and In-Vivo Bioequivalence Documentation (Guidance for Industry), US Government Printing Office, 1997.
10. Amidon G.L., Lennernas H., Shah V.P., Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 1995, 12:413-420.
11. The European Agency for the Evaluation of Medicinal Products (EMEA), Human Medicines Evaluation Unit, Committee for Proprietary Medicinal Products (CPMP), Note for Guidance on the Investigation of Bioavailability and Bioequivalence, 2001.
12. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System (Guidance for Industry), 2000.
13. World Health Organization, WHO Expert Committee on Specifications for Pharmaceutical Preparations - WHO Technical Report Series, No. 937: 40th Report, 2006.
14. Kovacevic I., Parojcic J., Homsek I., Tubic-Grozdanis M., Langguth P. Justification of biowaiver for carbamazepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simulation. Mol. Pharm. 2009, 6:40-47.
15. Kovacevic I., Parojci J., Tubi-Grozdanis M., Langguth P. An investigation into the importance of " very rapid dissolution" criteria for drug bioequivalence demonstration using gastrointestinal simulation technology. AAPS J. 2009, 11:381-384.
16. Okumu A., DiMaso M., Lobenberg R. Computer simulations using GastroPlus to justify a biowaiver for etoricoxib solid oral drug products. Eur. J. Pharm. Biopharm. 2009, 72:91-98.
17. Shono Y., Jantratid E., Janssen N., Kesisoglou F., Mao Y., Vertzoni M., Reppas C., Dressman J.B. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling. Eur. J. Pharm. Biopharm. 2009, 73:107-114.
18. Tubic-Grozdanis M., Bolger M.B., Langguth P. Application of gastrointestinal simulation for extensions for biowaivers of highly permeable compounds. AAPS J. 2008, 10:213-226.
19. Dressman J.B., Thelen K., Jantratid E. Towards quantitative prediction of oral drug absorption. Clin. Pharmacokinet. 2008, 47:655-667.
20. Sugano K. Introduction to computational oral absorption simulation. Expert Opin. Drug Metab. Toxicol. 2009, 5:259-293.
21. SimulationsPlus I. Simulations plus, Inc. Integrating Science and Software, 2009. (accessed 1.10.09). http://www.simulations-plus.com/Publication.aspx?pID=11.
22. Bayer Technology Services GmbH. Computational Systems Biology - Services and Solutions by Bayer Technology Services, 2009. (accessed 1.10.09). http://www.systems-biology.com/refs/pubs.html.
23. Jinno J., Kamada N., Miyake M., Yamada K., Mukai T., Odomi M., Toguchi H., Liversidge G.G., Higaki K., Kimura T. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J. Controlled Release 2006, 111:56-64.
24. Willmann S., Schmitt W., Keldenich J., Dressman J.B. A physiologic model for simulating gastrointestinal flow and drug absorption in rats. Pharm. Res. 2003, 20:1766-1771.
25. Willmann S., Edginton A.N., Dressman J.B. Development and validation of a physiology-based model for the prediction of oral absorption in monkeys. Pharm. Res. 2007, 24:1275-1282.
26. Willmann S., Schmitt W., Keldenich J., Lippert J., Dressman J.B. A physiological model for the estimation of the fraction dose absorbed in humans. J. Med. Chem. 2004, 47:4022-4031.
27. Andersen A.C. The Beagle as an Experimental Dog 1970, Iowa University Press, Ames, Iowa.
28. Kararli T.T. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm. Drug Dispos. 1995, 16:351-380.
29. Paulsen D.B., Buddington K.K., Buddington R.K. Dimensions and histologic characteristics of the small intestine of dogs during postnatal development. Am. J. Vet. Res. 2003, 64:618-626.
30. Miller M.E., Evans H.E. Milleŕs Anatomy of the Dog 1979, Saunders, Philadelphia.
31. Vaxman F., Lambert A., Grenier J.F. Small bowel biopsy by remote control: experimental study on dogs. Dig. Dis. Sci. 1996, 41:295-300.
32. Kuzmuk K.N., Swanson K.S., Tappenden K.A., Schook L.B., Fahey G.C. Diet and age affect intestinal morphology and large bowel fermentative end-product concentrations in senior and young adult dogs. J. Nutr. 2005, 135:1940-1945.
33. Taylor A.B., Anderson J.H. Scanning electron microscope observations of mammalian intestinal villi, intervillus floor and crypt tubules. Micron 1972, 3:430-453.
34. Anderson J.H., Taylor A.B. Scanning and transmission electron microscopic studies of jejunal microvilli of the rat, hamster and dog. J. Morphol. 1973, 141:281-291.
35. Dressman J.B. Comparison of canine and human gastrointestinal physiology. Pharm. Res. 1986, 3:123-131.
36. Katori N., Aoyagi N., Kojima S. Effects of atropine and loperamide on the agitating force and GI transit time in dogs in drug absorption studies. Biol. Pharm. Bull. 1996, 19:1338-1340.
37. Katori N., Aoyagi N., Kojima S. Effects of codeine on the agitating force and gastrointestinal transit time in dogs, for use in drug absorption studies. Biol. Pharm. Bull. 1998, 21:418-420.
38. Mizuta H., Kawazoe Y., Ogawa K. Effect of small intestinal transit time on gastrointestinal absorption of 2-[3-(3,5-di-tert-butyl-4-hydroxyphenyl)-1H-pyrazolo[3,4-b]pyridin-1-yl] ethyl acetate, a new non-steroidal anti-inflammatory agent. Chem. Pharm. Bull. (Tokyo) 1990, 38:2825-2828.
39. Mizuta H., Kawazoe Y., Ogawa K. Gastrointestinal absorption of chlorothiazide: evaluation of a method using salicylazosulfapyridine and acetaminophen as the marker compounds for determination of the gastrointestinal transit time in the dog. Chem. Pharm. Bull. (Tokyo) 1990, 38:2810-2813.
40. Sagara K., Nagamatsu Y., Yamada I., Kawata M., Mizuta H., Ogawa K. Bioavailability study of commercial sustained-release preparations of diclofenac sodium in gastrointestinal physiology regulated-dogs. Chem. Pharm. Bull. (Tokyo) 1992, 40:3303-3306.
41. Sagara K., Mizuta H., Ohshiko M., Shibata M., Haga K. Relationship between the phasic period of interdigestive migrating contraction and the systemic bioavailability of acetaminophen in dogs. Pharm. Res. 1995, 12:594-598.
42. Itoh T., Higuchi T., Gardner C.R., Caldwell L. Effect of particle size and food on gastric residence time of non-disintegrating solids in beagle dogs. J. Pharm. Pharmacol. 1986, 38:801-806.
43. Miyabayashi T., Morgan J.P., Atilola M.A.O., Muhumuza L. Small intestinal emptying time in normal beagle dogs. Vet. Radiol. 1986, 27:164-168.
44. Mizuta H., Kawazoe Y., Haga K., Ogawa K. Effects of meals on gastric emptying and small intestinal transit times of a suspension in the beagle dog assessed using acetaminophen and salicylazosulfapyridine as markers. Chem. Pharm. Bull. (Tokyo) 1990, 38:2224-2227.
45. Smeets-Peeters M., Watson T., Minekus M., Havenaar R. A review of the physiology of the canine digestive tract related to the development of in vitro systems. Nutr. Res. Rev. 1998, 11:45-69.
46. Lui C.Y., Amidon G.L., Berardi R.R., Fleisher D., Youngberg C., Dressman J.B. Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans. J. Pharm. Sci. 1986, 75:271-274.
47. Smith H.W. Observations on the flora of the alimentary tract of animals and factors affecting its composition. J. Pathol. Bacteriol. 1965, 89:95-122.
48. Youngberg C.A., Wlodyga J., Schmaltz S., Dressman J.B. Radiotelemetric determination of gastrointestinal pH in four healthy beagles. Am. J. Vet. Res. 1985, 46:1516-1521.
49. Pinkel D. The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res. 1958, 18:853-856.
50. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers (Guidance for Industry and Reviewers), 2002.
51. Kawai R., Lemaire M., Steimer J.L., Bruelisauer A., Niederberger W., Rowland M. Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125. J. Pharmacokinet. Biopharm. 1994, 22:327-365.
52. Adachi H., Strauss W., Ochi H., Wagner H.N. The effect of hypoxia on the regional distribution of cardiac output in the dog. Circ. Res. 1976, 39:314-319.
53. Davies B., Morris T. Physiological parameters in laboratory animals and humans. Pharm. Res. 1993, 10:1093-1095.
54. Quillen E.W., Reid I.A. Effect of intravertebral angiotensin II on cardiac output and its distribution in conscious dogs. Circ. Res. 1988, 63:702-711.
55. Johnson K.C. Dissolution and absorption modeling: model expansion to simulate the effects of precipitation, water absorption, longitudinally changing intestinal permeability, and controlled release on drug absorption. Drug Dev. Ind. Pharm. 2003, 29:833-842.
56. Liversidge G.G., Cundy K.C. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int. J. Pharm. 1995, 125:91-97.
57. Merisko-Liversidge E., Liversidge G.G., Cooper E.R. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. 2003, 18:113-120.
58. Wu Y., Loper A., Landis E., Hettrick L., Novak L., Lynn K., Chen C., Thompson K., Higgins R., Batra U., et al. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int. J. Pharm. 2004, 285:135-146.
59. Dressman J.B., Amidon G.L., Reppas C., Shah V.P. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm. Res. 1998, 15:11-22.
60. Jantratid E., Janssen N., Reppas C., Dressman J.B. Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm. Res. 2008, 25:1663-1676.
61. Bayer Technology Services GmbH, PK-Sim User Manual and Software, 4.1, 2009.
62. Toyobuku H., Tamai I., Ueno K., Tsuji A. Limited influence of P-glycoprotein on small-intestinal absorption of cilostazol, a high absorptive permeability drug. J. Pharm. Sci. 2003, 92:2249-2259.
63. Kuentz M., Nick S., Parrott N., Rothlisberger D. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. Eur. J. Pharm. Sci. 2006, 27:91-99.
64. Lukacova V., Woltosz W.S., Bolger M.B. Prediction of modified release pharmacokinetics and pharmacodynamics from in vitro, immediate release, and intravenous data. AAPS J. 2009, 11:323-334.
65. Okumu A., DiMaso M., Lobenberg R. Dynamic dissolution testing to establish in vitro/in vivo correlations for montelukast sodium, a poorly soluble drug. Pharm. Res. 2008, 25:2778-2785.
66. Thelen K., Jantratid E., Dressman J.B., Lippert J., Willmann S. Analysis of nifedipine absorption from soft gelatin capsules using PBPK modeling and biorelevant dissolution testing. J. Pharm. Sci. 2010, 99:2899-2904.
67. Parrott N., Lukacova V., Fraczkiewicz G., Bolger M.B. Predicting pharmacokinetics of drugs using physiologically based modeling - application to food effects. AAPS J. 2009, 11:45-53.
68. Wishart D.S., Knox C., Guo A.C., Shrivastava S., Hassanali M., Stothard P., Chang Z., Woolsey J. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006, 34:668-672.
69. Wishart D.S., Knox C., Guo A.C., Cheng D., Shrivastava S., Tzur D., Gautam B., Hassanali M. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008, 36:901-906.
70. Rodgers T., Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J. Pharm. Sci. 2006, 95:1238-1257.
71. Heng D., Cutler D.J., Chan H.-K., Yun J., Rap J.A. Dissolution kinetic behavior of drug nanoparticles and their conformity to the diffusion model. Langmuir 2008, 24:7538-7544.
72. Sugano K. Theoretical comparison of hydrodynamic diffusion layer models used for dissolution simulation in drug discovery and development. Int. J. Pharm. 2008, 363:73-77.
73. Parrott N., Lukacova V., Fraczkiewicz G., Bolger M.B. Predicting pharmacokinetics of drugs using physiologically based modeling-application to food effects. AAPS J. 2009, 11:45-53.